Skip to content
  • ABOUT
        • MISSION/HISTORY
        • DIRECTORS/STAFF
        • SUPPORT
        • INTERNSHIPS
        • FINANCIAL INFORMATION
        • JOBS
        • CONTACT US
  • WASTEWATCHER
  • MEDIA
        • CONGRESSIONAL RATINGS
        • PORKER OF THE MONTH
        • PRESS RELEASES
        • COMMENTARY
  • ISSUES
    • CONGRESSIONAL PIG BOOK
      • Earmark Database
      • PRIME CUTS
      • ISSUE BRIEFS
      • AGENCY COMMENTS
    • DEFENSE
      • AVIATION & SPACE
      • F-35 JOINT STRIKE FIGHTER
      • PROCUREMENT
    • INNOVATION & TECHNOLOGY POLICY CENTER
      • ANTITRUST
      • ARTIFICIAL INTELLIGENCE
      • BIOPHARMACEUTICALS
      • INTELLECTUAL PROPERTY
      • PRIVACY
      • TECHNOLOGY AND INNOVATION
      • TELECOMMUNICATIONS
    • GENERAL WASTE
      • AGRICULTURE REFORM
      • POSTAL SERVICE
      • TAXES
      • TRANSPORTATION
    • HEALTH AND SCIENCE
      • PRICE CONTROLS
      • GOVERNMENT RUN HEALTHCARE
      • 340B DRUG DISCOUNT PROGRAM
      • PHARMACY BENEFIT MANAGERS
      • TOBACCO HARM REDUCTION
    • STATE ISSUES
  • ITPC
        • ANTITRUST
        • ARTIFICIAL INTELLIGENCE
        • BIOPHARMACEUTICALS
        • INTELLECTUAL PROPERTY
        • PRIVACY
        • TECHNOLOGY AND INNOVATION
        • TELECOMMUNICATIONS
  • CCAGW
DONATE
Facebook X-twitter Icon-instagram-1 Icon-youtube

Pharmaceuticals

340B, Entitlements, General Waste, Healthcare, Pharmaceuticals

Price Controls on Medicaid Would Be Disastrous and Fail to Cut Wasteful Spending

May 4, 2025 Eric Maus

President Trump has made government efficiency a top priority.  These efforts include eliminating improper payments and ensuring that only those who are eligible for government programs receive the benefits, including Medicaid.  As President Trump said on “Meet the Press” on Sunday, May 4, 2025, “if illegal immigrants are in the mix, if people that aren’t […]

USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
Healthcare, Intellectual Property, Pharmaceuticals

USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP

September 6, 2024 Deborah Collier

USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.

Not-So-Happy Birthday to the Inflation Reduction Act
Biopharmaceuticals, General Waste, Healthcare, Medicare, Pharmaceuticals

Not-So-Happy Birthday to the Inflation Reduction Act

August 15, 2024 Christina Smith

The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.

General Waste, Healthcare, Intellectual Property, International, Pharmaceuticals, States

FDA Hurts Patients By Authorizing Florida’s Drug Importation Program

January 12, 2024 Christina Smith

On January 5, 2024, the U.S. FDA authorized Florida’s drug importation program. 

General Waste, Healthcare, Intellectual Property, Pharmaceuticals

Misguided Use of March-In Rights Will Harm Patients

December 6, 2023 Christina Smith

The use of march-in rights to steal intellectual property will neither lower costs nor create more access to healthcare.

General Waste, Healthcare, Intellectual Property, Medicare, Pharmaceuticals

Biden Price Controls Kill Innovation and Patients

October 6, 2023 Christina Smith

 IRA drug price controls will devastate future drug development, resulting in more lives lost.

General Waste, Healthcare, Medicare, Pharmaceuticals

Congress Should not Double Down on Devastating Drug Price Controls

August 1, 2023 Christina Smith

House Democrats’ new bill on price controls will devastate future drug development and raise costs. 

Biopharmaceuticals, General Waste, Healthcare, Intellectual Property, Pharmaceuticals, Regulations

Biden’s Budget and the SMART Prices Act Will Devastate Drug Development

June 24, 2023 Thomas Schatz

Pharmaceutical price controls in President Biden’s budget and the SMART Choices Act will devastate drug development.

General Waste, Healthcare, Pharmaceuticals

Patients Pay the Ultimate Price for Price Controls

February 17, 2023 Christina Smith

Price controls on pharmaceuticals distort the medical marketplace and will not lower drug prices. 

Citizens Against Government Waste Releases Analysis of Minnesota Opioid Tax
340B, General Waste, Government Waste, Healthcare, Oversight, Pharmaceuticals

New Study Confirms 340B Program is Exploited

December 3, 2021 Elizabeth Wright

A new study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” shows the program is misused.

Posts pagination

Previous 1 2 3 Next

Search

Citizens Against Government Waste works to eliminate waste, fraud, abuse, and mismanagement in government through research and public education.

  • MISSION/HISTORY
  • DIRRECTORS/STAFF
  • SUPPORT
  • FINANCIAL INFORMATION
  • CONTACT US
  • CCAGW
  • 1-800-USA-DEBT ®
  • MEDIA@CAGW.ORG
  • 317 MASSACHUSETTS AVENUE, N.E.
    SUITE 300
    WASHINGTON, D.C. 20002

© Citizens Against Government Waste